The highly conserved C-terminus of the M protein of group A streptococcus (GAS) is a promising vaccine candidate. An epitope within the conserved C-terminus of the M protein, peptide 145 (a 20-mer with the sequence: LRRDLDASREAKKQVEKALE), has been defined which is the target of opsonic antibodies in both humans and mice, and is recognized by the sera of most adults living in areas of high streptococcal exposure. However, due to potential cross-reactivity between T cells stimulated by this region of the M protein and host cardiac myosin, it is critical to define precisely the minimal protective epitopes within p145. Studies have shown that the immunodominant epitope expressed by p145 is conformational, occurring as an α-helical coiled-coil. To enable us to map the murine minimal B cell and T cell epitopes within p145, we have used a novel strategy that allowed us to present shorter sequences of p145 in a native-like conformation. The minimal B cell epitope was found to be contained within residues 7-20 of the p145 sequence, and we have shown that mice immunized with this region are able to generate antibodies that bind to and also opsonize the organism GAS. The T cell epitope is located at the N-terminal region of the p145 sequence, residues 3-14. We have managed, therefore, to define a vaccine candidate-a minimal opsonic B cell epitope within the p145 sequence-that does not incorporate a potentially deleterious T cell epitope.
Introduction
Group A streptococcus (GAS) is a human pathogen that causes a number of diseases, including pharyngitis and impetigo. In a small percentage of individuals that are left untreated or are treated ineffectively with antibiotics, the streptococcal infection can lead to more serious illnesses such as rheumatic fever (RF) and rheumatic heart disease (RHD). In many developing countries, and among the indigenous populations of developed countries, RF and RHD account for half of all cardiovascular disease in children and young adults (1, 2) . Since RF and RHD only ever follow infection with group A streptococci, a streptococcal vaccine is an attractive strategy to prevent these diseases (3) .
Protection against GAS infection is believed to be mediated predominantly by opsonic antibodies directed against the N-terminal domain of the M protein, thereby making it susceptible to neutrophil-mediated phagocytosis (4) . The protective value of these antibodies has nominated the M protein, located on the surface of the bacterium, as a prime vaccine candidate. Two major considerations, however, hinder the development of such a vaccine. Firstly, there are Ͼ80 recognized serotypes of the M protein and the protective N-terminal specific antibodies against one serotype do not offer protection against other serotypes (4) . Secondly, immunological cross-reactivity between the M protein and host tissue, including the heart, has prompted concern that a streptococcal vaccine based on the M protein may evoke autoimmune pathology in humans (5) (6) (7) (8) .
To overcome the obstacle of antigenic polymorphism, one vaccine strategy is to raise protective antibodies against antigenic epitopes which are common to the large number of serological variants. Whilst the N-terminal domain encodes serotype-specific determinants, the C-terminal domain is highly conserved. The merit of epitopes from within the conserved region as possible vaccine candidates has been demonstrated by recent challenge experiments in laboratory mice. Following intranasal immunization with a mixture of peptides from the conserved region, mice showed a significant lowering of pharyngeal colonization rates upon challenge. The protective effect was evident following heterologous GAS challenge (9) (10) (11) . An epitope within the conserved C-terminus of the M protein, referred to as peptide 145 (12) (sequence in single letter amino acids: LRRDLDASREAKKQVEKALE), is known to be recognized by antibodies in the sera of most adults living in areas of high streptococcal exposure (13) and the sequence of this peptide overlaps one of the peptides that induced protection in mice. Although sera and mAb specific for certain conserved region epitopes have been shown to be non-opsonic (14) , both affinity-purified p145-specific human antibodies (15, 16) as well as antibodies induced in mice following immunization with p145 (12) are capable of opsonizing streptococci. Multiple serotypes of GAS can be opsonized by antibodies induced in mice by vaccination (13) , suggesting that this peptide might be an ideal vaccine candidate. However, although antibodies raised in mice to p145 displayed minimal heart reactivity by Western blot (12), T cells specific for peptides from the conserved region of the M protein, including p145, have been shown to react to cardiac myosin peptides and human heart (17) . Our approach to produce a safe, effective vaccine based on p145, as described in this report, is to define the minimal antibody epitope on p145 that is not also recognized by T cells, and to ask whether this minimal epitope can induce antibodies specific for p145 as well as the bacteria. Within the conserved region, the M protein is known to contain an α-helical coiled-coil structure (18) and p145 itself also has helical potential (19) . In order to define minimal peptide sequences recognized by antibodies, we used a strategy based on 'chimeric' peptides in which small peptides from within the p145 sequence are placed within the sequence of other peptides known to form α-helices (19) . Thus the structure of the minimal epitopes can be maintained. Such peptides were recently used to demonstrate that sera from humans living in endemic areas recognized sequences within p145 (15, 19) . In this study we have now used this approach to define precisely the regions of p145 recognized by antibodies and T cells from mice immunized with p145, and to then ask whether an immunogen defined on the basis of recognition by antibodies, but not the target of p145-specific T cells, could induce antibodies that recognize p145 as well as bacteria.
Methods

Mice
The following strains of H-2 congenic mice were used: B10.BR (H-2 k ), B10.D2/n2 (H-2 d ), B10 (H-2 b ) and B10.A(4R) (H-2 h4 ). All mice were obtained from the Animal Resources Centre, Willetton, Western Australia.
Antibody production
Male mice, 5-6 weeks old, four per group, were immunized s.c. at the tail base with 30 µg of peptide emulsified in complete Freund's adjuvant (CFA) (a total of 50 µl was administered). Four subsequent booster injections of 30 µg of peptide dissolved in PBS were given at 10 day intervals. Before each boost, mice were bled via the tail artery, and sera prepared and stored at -20°C until used.
ELISA
Peptides were diluted to 0.5 µg/ml (1 µg/ml for insert peptides) in carbonate coating buffer, pH 9.6, and coated onto polyvinyl plates (ICN, Irvine, CA) in a volume of 100 µl/well overnight at 4°C. The peptide was removed and the wells blocked with 150 µl of 5% skim milk PBS-Tween 20 for 2 h at 37°C (or overnight at 4°C). The plates were then washed 3 times with PBS-Tween 20 buffer. Mouse antisera were serially diluted in 0.5% skim milk PBS-Tween 20 buffer, starting at an initial dilution of 1:100 to a final dilution of 1:12,800. Each sample was diluted to a final volume of 100 µl and incubated for 1.5 h at 37°C. The plates were washed 5 times and peroxidaseconjugated goat anti-mouse IgG (Tago, Burmingham, CA) added at a dilution of 1:3000 in 0.5% skim milk PBS-Tween 20 for 1.5 h at 37°C. After washing, 100 µl of OPD substrate (Sigma, St Louis, MO) was added according to the manufacturers' instructions and incubated at room temperature for 30 min in the dark. The absorbance was measured at 450 nm in an ELISA reader (Multiscan; ICN Flow, CA). The titer was defined as the lowest dilution that gave an absorbance of Ͼ3 SD above the mean absorbance of control wells (containing normal mouse serum). As previously described (20) , the total concentration of mouse antibody (µg/ml) can be determined by the construction of a standard curve where known concentrations of mouse IgG are plotted against the optical density at 450 nm.
T cell proliferation assay
Mice were immunized s.c. at the tail base with 30 µg of peptide emulsified in CFA. Eight days later, draining lymph node cells were pooled and plated in triplicate at 2ϫ10 6 /well in flat-bottomed microtiter plates with complete EMEM medium containing 1-2% heat-inactivated normal mouse serum (Trace Biosciences, Victoria, Australia). The plates were placed in a humidified 5% CO 2 /air incubator for 4 days at 37°C. Following incubation, cultures were pulsed with 0.5 µCi of [ 3 H]thymidine for 16 h. Incorporation of label was measured by liquid scintillation spectroscopy using a Betaplate counter. Lymphocyte activation was measured by estimating the stimulation index (SI ϭ c.p.m. in presence of antigen/c.p.m. in absence of antigen).
Preparation of mouse heart antigen
Three mice were sacrificed and the hearts removed. The hearts were cut into smaller pieces and ground with a mortar and pestle in 3 ml of sterile cold PBS, pH 7.4. The liquid was removed and centrifuged at 3000 r.p.m. for 10 min at 4°C. The supernatant was decanted and kept at -20°C until used. Protein concentration was determined using the BioRad Protein Assay as per the manufacturers' instructions (BioRad, San Diego, CA).
Bactericidal assay
Murine antibodies were assayed for opsonic activity against M5 GAS as previously reported (12, 13, 15, 21) . Briefly, M5 GAS were cultured overnight (a minimum of 16 h) in 5 ml of Todd-Hewitt broth at 37°C. Before the assay, the bacteria were diluted to 10 -5 in normal sterile saline. Then, 50 µl of the bacterial dilution was added to 50 µl of heat-inactivated (10 min at 60°C) normal mouse serum or heat-inactivated immune serum. Heparinized non-opsonic human blood (400 µl) was added to the mixture and the tubes incubated for 3 h at 37°C with gentle rocking. Fifty microlitres of the 3 h culture was mixed with 20 ml of horse blood agar and poured onto bacteria plates. The number of colonies on each plate was counted after a 24 h incubation at 37°C. The percentage reduction in c.f.u. of bacteria was determined by counting the number of colonies growing after incubation with immune sera and comparing this to the number of colonies growing after incubation in control sera.
Complement fixation assay
This assay was a modification of that outlined by Hudson and Hay (22) and Jones and Fischetti (14) . All dilutions were made in barbitone-buffered saline. The reaction mixture consisted of 50 µl of antigen (M5 GAS diluted to OD 650 ϭ 0.25), 50 µl of immune sera and 50 µl of guinea pig complement in V-bottomed microtiter plates (Nunc Products, Roskilde, Denmark). Plates were incubated at 37°C for 30 min, after which 50 µl of sensitized sheep red blood cells (SRBC) were added and incubated for an additional 30 min at 37°C. Plates were then centrifuged at 800 r.p.m. for 10 min. The plates were examined for the presence of unlysed SRBC indicating complement fixation. The end-point titer of this test was taken as the first well showing~50% lysis of the indicator cells. mAb mAb were produced from BALB/c mice hyperimmunized i.p. with p145 coupled to diphtheria toxoid, and were selected, cloned, stored and maintained as previously described (23) . Five p145-specific mAb were used in this study, and were designated 6D12, 2A8, 8G9, 3B12 and 2B10. One nonspecific mAb, 6E253 (an antibody directed against malarial MSP-1 protein), was also included.
Peptides
The peptides used in this study were synthesized by the teabag method (24) . Crude peptides were purified on a reversephase HPLC column (BioRad) and the homogeneity of the purified peptides determined by reverse-phase HPLC and laser-desorption time-of-flight mass spectrometry (LaserMat; FinniganMat, UK). The sequences of p145, the chimeric peptides (J1-J9 and J14), the shorter J 'inserts' (J I 1-J I 9) and Jcon, which were previously described (19) , are given in Table  1 . Stock peptides were dissolved in PBS at a concentration of 10 mg/ml and stored at -20°C.
Results
Mapping the B cell epitope within p145
We have previously shown that p145 stimulates peptidespecific antibodies in B10.BR mice (12) . To determine the 
Bold residues are those contained within p145.
minimal antibody epitope recognized following immunization with p145, two strategies were employed: sera from peptideimmunized mice were tested for ability to bind the panel of chimeric peptides and linear peptides (Table 1) ; and the epitope specificities of hybridomas from diphtheria toxoidp145 immunized BALB/c mice were similarly examined. Sera from 18 individual B10.BR mice with titers to p145 ranging from Ͻ1600 to Ͼ12,800 were thus tested in an ELISA for their ability to bind the conformationally constrained chimeric peptides (J1-J9) as well as the short linear peptides containing only p145 sequences (J I 1-J I 9). All these peptides contained 12 sequential amino acids from p145 and the sequence of each peptide in the series was offset from the previous peptide by one amino acid. The sera from nine mice with a p145-specific antibody titer Ͼ12,800 contained antibodies which bound most strongly to J7 and J8, with three also recognizing J9 (Table 2) . Eight of the 18 sera were observed to bind the short insert peptides, particularly J I 5, although the titer was often low, suggesting the presence of additional linear epitopes within the p145 sequence. However, serum from only one mouse contained antibodies which bound J I 8, which contained the identical p145-derived sequences as the chimeric peptide J8. Thus, the murine B cell epitope within p145 was represented by the sequence ASREAKKQV-EKALE and it appears likely that the epitope is conformational. However, since we have not shown that equivalent amounts of shorter insert peptides and chimeric peptides are bound to the plate nor what minimal epitopes are adequately displayed by these bound peptides, we cannot prove that the epitope is conformational. However, antibodies raised to the 
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Legend: ϩϩϩ titer Ͼ12,800; ϩϩ titer 6400-12,800; ϩ titer 3200-6400; -titer Ͻ1600.
smaller peptides bind strongly to the smaller peptides (data not shown) and the other chimeric peptides are recognized by different sera (19) . No p145-specific antisera tested bound to the control (Jcon) peptide (Table 2) . mAb were generated following immunization of BALB/c mice and were tested in an ELISA for their specificity. Antibodies from all supernatants, except 2B10, bound strongly to peptides 145 and J8 (titer Ͼ12,800), with a lower recognition of peptides J7 and J2 (titer 1600-12,800) ( Table 3 ). The mAb 6D12 also recognized peptide J9 (titer Ͼ12,800). The mAb 2B10 was found to predominantly recognize p144 (titer Ͼ12,800), a peptide also contained within the conserved C-terminal of the M protein that overlaps the first 10 amino acids of the p145 sequence ( Table 1) . As a consequence, it bound strongly to peptides J1 and J2 (titer Ͼ12,800), with some recognition of J8 (titer 3200-6400). The Jcon peptide was not recognized by the mAb (Table 3 ). The non-specific mAb, 6E253, did not recognize p145, the J chimeric peptides or the insert peptides.
Immunogenicity of defined epitopes B10.BR mice were immunized with peptides J1 to J9 s.c. Following the initial immunization and four subsequent boosts, three chimeric peptides, J1, J4 and J6, did not generate an antibody response (Table 4) . A moderate response (titer 3200-12,800) was observed with peptides J2, J3 and J5, whilst a significantly higher antibody response (titer Ͼ12,800) was obtained from the serum of mice immunized with peptides J7, J8 and J9 (Table 4) . However, of all the peptides (J1-J9), only J8 was able to induce an antibody response to p145. We do not know why certain chimeric peptides were incapable of inducing an antibody response to themselves (J1, J4 and J6) but this could indicate that these peptides do not contain T cell epitopes.
Since the antisera and hybridomas from mice immunized with p145 were seen to recognize predominantly J7, J8 and J9, an additional chimeric peptide was synthesized that included amino acids 7-20 of the p145 sequence (those amino acids found within J7, J8 or J9), termed J14 (Table 1) . 
Blank squares denote samples that were not tested. Peptide 145 antisera bound to pJ14 in an ELISA (Table 4) and the antisera from mice immunized with J14 bound to the parent peptides of J7, J8, J9 and p145 (Table 4) . Thus, two chimeric peptides have been defined which are capable of inducing anti-p145 antibodies.
The immunogenicity of peptides 145 and J8 was also examined in three additional H-2 congenic strains of mice on the B10 background [B10.D2, B10.A(4R) and B10]. Following the initial immunization in CFA and three further boosts in PBS, the B10 mice were not able to generate an antibody response to either peptide (Table 5) . Peptide J8 was able to induce antibody production in B10.A(4R) mice, but p145 was not (Table 5 ). Both peptides induced antibody production in the B10.D2/n2 and B10.BR mice, but in both cases the antibody response to J8 was much stronger than that induced by p145 (Table 5) .
Determination of the T cell epitope within peptide 145
To determine the location of the T cell epitope(s) within the p145 sequence, lymph node cells from mice primed in vivo with p145 were challenged in vitro with the same peptide, the chimeric J1-J9 peptides and the linear J I 1-J I 9 inserts. Lymph node cells were also checked for cross-reactivity in vitro with myosin peptides, tropomyosin, myosin, keratin, human heart extract and mouse heart extract. All antigens were plated at a concentration of 30 µg/well, which has previously been shown to be the optimal concentration for murine T cell responses (17) . We could repeatedly demonstrate significant proliferative responses (SI Ͼ 5) to p145, J3, J I 3 and purified protein derivative (PPD) (positive control), with much lower responses to J4 and J I 4, suggesting that the T cell epitope lies within the sequence of RDLDASREAKKQ (Fig. 1) . Minimal responses were observed to tropomyosin, myosin, human heart extract and mouse heart extract (SI Ͻ 5); however, a significant response was observed to keratin (SI ϭ 7.8), also a coiled-coil protein (25) . Lymph node cells from mice immunized with PBS and CFA alone did not proliferate to p145 or the J chimeric peptides (data not shown).
Lymph node cells from mice primed in vivo with peptides J8 and J14 were challenged in vitro with the immunizing peptide, the parent peptide (p145), and were also checked for cross-reactivity with human heart extract, tropomyosin, myosin, keratin and homologous myosin peptides. T cells from such mice did not proliferate significantly in the presence of p145, cardiac peptides or keratin (Fig. 2) , but did respond to the immunizing peptide.
Opsonization with serum antibodies specific for peptides 145, J8 and J14
Antibodies from mice immunized with peptides 145, J8 and J14 were tested for their ability to kill M5 GAS in a bactericidal assay. As shown in Table 6 , the level of opsonic activity displayed by p145 antisera is correlated to the titer ranging from 64% bactericidal activity at a titer of Ͼ12,800 to 55% at a titer of 6400 and 15% at a titer of 400. This has also been observed in a previous study in our laboratory (13) . All antisera were predominantly of the IgG2b isotype, as shown by ELISA, except one sample (M3) which was IgG2a. Peptide J8 was more immunogenic than p145, with all mice having a titer of Ͼ12,800 with mean bactericidal activity at 49%. A higher range of opsonic activity was observed with the antisera from mice that had been immunized with J14 (60-74%) ( Table 6) and titers exceeded 12,800. All J8 and J14 antisera were of the IgG2b isotype.
We have previously shown that antibodies to the N-terminal epitope from M5 GAS (p160) completely opsonize M5 GAS (13) . In all opsonization assays in this study, anti-p160 antisera was used as a positive control. As shown in Table 6 , p160 antisera exhibited a potent bactericidal activity, with a 92-98% reduction in colony counts.
Complement fixation by serum antibodies specific for peptides 145, J8 and J14
The complement fixation test is a classic immunological method used for demonstrating the presence of antibody in immune serum (14, 22) . We have used this test to ask whether anti-peptide antibodies bind the organism GAS. The test consists of two separate parts. In the first part, serial dilutions of the immune serum (p145, J8 and J14) are added to M5 GAS with a limited amount of guinea pig complement. If the immune serum contains antibody to the antigen, the resulting antibody-antigen complex will bind all the complement added. The second part involves the addition of sensitized SRBC (SRBC coated with anti-SRBC antibodies). If there is free complement left in the wells, the SRBC will lyse. A positive result is revealed by the failure of the sensitized SRBC to lyse, due to the complement being fixed by the antibodyantigen complex. Lysis of the indicator cells indicates the lack of antigen binding antibodies and no complement fixation.
Sensitized SRBC placed in the wells with pooled antisera from mice immunized with peptides 145, J8 and J14, and M5 GAS and complement did not lyse, confirming that antibodyantigen complexes had been formed and complement had been fixed. Using a standard ELISA and serial dilution, the concentration of antibody in the wells which displayed 50% lysis of the SRBC was determined. The concentration of p145-antisera required for 50% lysis was 22.4 µg/ml, the concentration of J8 antibodies required was 10.8 µg/ml and the concentration of J14 antibodies required was 55 µg/ml ( Table 7 ). The isotype of the anti-peptide serum was found to a Guinea pig complement fixation by immune sera reacted with M5 GAS. Values are expressed as the amount of antibody (µg/ml) needed for 50% lysis of sensitized SRBC when complexed with an optimal concentration of M5 cells (OD 650 ϭ 0.25).
b The titer of the pooled immune sera to the immunizing peptide.
be predominantly IgG2b and also displayed opsonic activity (Tables 6 and 7) . Normal mouse serum from control mice was used as a negative control. The sera did not bind to the M5 GAS and, therefore, could not fix the complement, resulting in 100% lysis of the sensitized SRBC at all dilutions of the serum (data not shown).
Pooled antisera from mice immunized with p160 was seen to require the lowest concentration of antibody to cause 50% lysis of the sensitized SRBC (1 µg/ml) ( Table 7 ). This level of binding to the M5 GAS is reflected in the opsonic activity of p160 sera in a bactericidal assay (92-98%) ( Table 6 ). This serum was also predominantly of the IgG2b isotype (Table 7) .
Discussion
In this study, we have used a novel strategy to map the minimal B cell and T cell epitopes recognized following immunization with peptide 145, a 20-mer located within the conserved C-repeat region of the M protein of GAS and which is a target of human opsonic antibodies against multiple serotypes of the organism. We have demonstrated that a 28-mer peptide, containing only 12 amino acids from the p145 sequence, is able to generate opsonic murine antibodies without simultaneously stimulating host-reactive T cells. Antibodies to p145 were found in the sera of 90% of adult Australian Aboriginal subjects and 81% of adult Thai subjects living in streptococcal endemic areas. In contrast, only 10% of Caucasian subjects with low exposure to GAS showed positive responses (13) . Their prevalence increased with age paralleling the acquisition of natural streptococcal immunity, being present in~40% of Aboriginal children and 90% of adults (15) . Furthermore human p145-specific antibodies were able to opsonize multiple serotypes of GAS in a bactericidal assay (15) . It is possible, therefore, that antibodies to p145 contribute significantly to immunity.
We have previously shown that human p145-specific antibodies recognize conformational epitopes. To enable us to map the regions of p145 recognized following immunization a strategy was used whereby short fragments of the p145 sequence were inserted into the framework of a larger peptide which would maintain the helical structure. The 20 amino acid sequence of p145 was split into a series of nine 12-mer peptides in which the window of p145 sequence was shifted across one amino acid residue at a time. Each of the shorter 'J insert' sequences was then placed into the framework of the larger coiled-coil structure of Jcon. The flanking Jcon peptide was derived from the sequence of the GCN4 protein, a DNA binding protein in yeast. A few residues of the GCN4 peptide were conservatively changed to decrease the potential homology between the Jcon peptide and cardiac proteins. The series of nine 28-mer 'J peptides' were then used for epitope definition. The sequence of the flanking peptides differed slightly for each chimeric peptide in order to maintain the correct periodicity of hydrophobic residues necessary to maintain helical structure (19) .
We have shown that murine p145 antisera recognizes predominantly J7, J8 and J9 in an ELISA. When mice are immunized with one of the three peptides, only peptide J8 is able to stimulate the production of antibodies which recognize the parent peptide (p145) and can opsonize M5 GAS in a bactericidal assay. This is also the case with antisera from mice that have been immunized with peptide J14.
Two human studies have examined the fine specificity of antibody recognition of sequences in the p145 region. In one study of individuals living in a streptococcal-endemic environment, recognition was predominantly of J7/J8 and J1/ J2 (15) . In a study of a different group of individuals living in an endemic environment, recognition was predominantly of J2 (19) . Individuals in the endemic environment without antip145 antibodies do not have antibodies that bind to the chimeric peptides. In this study, mice immunized with p145 responded primarily to J7/J8. J2 was recognized by antibodies from one of 18 mice immunized with p145. Curiously, there was slight recognition of J2 by the mAb generated to p145 even though their primary response was to J7 and J8, demonstrating some immunological cross-reactivity between these two sequences. Collectively, these data show that natural streptococcal exposure and deliberate peptide immunization induce antibodies of very similar fine specificities for conformational epitopes, and suggest that the same conformational epitopes are displayed on the surface of the bacterium as on p145. The differential response of the two human groups to J2 and J7/J8 may indicate exposure to different organisms which might have fine sequence differences in the C-terminal half of p145 or possibly to different genetic regulation of the fine antibody response to minimal epitopes. Table 8 lists the available sequences for sequenced M proteins in the region of p145 and show that, while p145 is highly conserved, the sequence changes that do occur are mostly contained within the J7/J8 region.
The development of a GAS vaccine based on the M protein has been hindered due to the potential ability of M protein antigens to evoke potentially harmful host reactions. Sera from individuals with RF have been shown to have circulating antibodies that bind to human heart tissue in vitro, whilst patients recovering from uncomplicated streptococcal pharyngitis and from streptococcal infections unassociated with RF, such as pyoderma, also demonstrate low titers of antibodies to cardiac tissue (26) . We have previously examined the immunogenicity of p145 (12) and have shown that antibodies induced to it showed only minimal reactivity to human heart tissue in an immunoblot when compared with antibodies to the pepM5 fragment of the M protein (the N-terminal 197 amino acid fragment) (27) and antibodies to other peptide sequences from the conserved C-terminal region. However, human T cells specific for p145 can react to myosin peptides and heart tissue (17) .
Peptide 145 does not stimulate T cells from B10.BR mice which react with heart, but does stimulate keratin-specific T cells (Fig. 1) . The murine T cell epitope for p145 has been shown to be located within pJ I 3 (amino acids 3-14 of the p145 sequence). The T cells isolated from mice primed with pJ8 and pJ14, however, do not proliferate in the presence of p145, keratin, heart extract, myosin, tropomyosin or myosin homologous peptides. Furthermore, they do not proliferate to the Jcon peptide. Since J8 and J14 do stimulate T cells, the T cell epitope is likely to be formed by the sequence spanning the p145 insert segment and the flanking region. Peptides J8 and J14, therefore, are able to induce the production of opsonic antibodies in mice but do not stimulate potentially cross-reactive T cells. We have managed, therefore, to define the minimal opsonic B cell epitope within the p145 sequence and show that it does not incorporate a deleterious T cell epitope.
